SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a developer of medical devices for the treatment of neurological diseases and disorders, announces that preliminary data from its PROSPECT feasibility study is being presented today at the Congress of Neurological Surgeons in San Diego by Brian Kopell, M.D. of the Medical College of Wisconsin’s Department of Neurosurgery. Initial results on ten of the total 12 subjects in the study indicate that Northstar’s cortical stimulation therapy* contributed to an overall decrease in severity of depression and an overall increase in psychological functioning.
